GT Biopharma (GTBP) News
NASDAQ: GTBPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
2.96-0.22 (-6.92%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
GTBP news summary
We found 3 recent headlines mentioning GT Biopharma (GTBP): 1 in the past week and 3 in the past 30 days, most often from GlobeNewswire, Nasdaq. GTBP is making an outsized move today, down 6.92% at $2.96, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "GT Biopharma Reports Third Quarter 2026 Financial Results", was published by GlobeNewswire on Nov 16, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest GT Biopharma headlines
- GT Biopharma Reports Third Quarter 2026 Financial ResultsPhase 1 trial evaluating GTB-3650 TriKE ® remains ongoing, with an update anticipated in Q4 2026GlobeNewswire
- GT Biopharma, Inc. Stockholders Approve Increase in Authorized Shares to 250,000,000 and Share Issuance ProposalGT Biopharma, Inc. held a Special Meeting of Stockholders on November 11, 2026, at which a total of 1,146,416 shares of common stock, representing approximately 55.62% of the eligible shares, were…Nasdaq
- GT Biopharma Selected for Oral Presentation at the SITC 2026 Annual MeetingSAN FRANCISCO, CALIFORNIA, Oct. 26, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics…GlobeNewswire